Related references
Note: Only part of the references are listed.CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
Jing Xi et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immune gene expression and response to chemotherapy in advanced breast cancer
Theodoros Foukakis et al.
BRITISH JOURNAL OF CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine
Alexios Matikas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Edith A. Perez et al.
LANCET ONCOLOGY (2015)
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?
Marta Bonotto et al.
ONCOLOGIST (2015)
Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer
In Hae Park et al.
Clinical Breast Cancer (2014)
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence
C. M. Booth et al.
BRITISH JOURNAL OF CANCER (2014)
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
Chikako Suzuki et al.
MEDICAL ONCOLOGY (2013)
Combination versus sequential single agent chemotherapy for metastatic breast cancer
Rachel F. Dear et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
Theodoros Foukakis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Single agent versus combination chemotherapy for metastatic breast cancer
Sue Carrick et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2009)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
Daniel F. Hayes et al.
CLINICAL CANCER RESEARCH (2006)
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
A Hackshaw et al.
BRITISH JOURNAL OF CANCER (2005)
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
P Bruzzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Goals and objectives in the management of metastatic breast cancer
CT Chung et al.
ONCOLOGIST (2003)
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
F Cardoso et al.
ANNALS OF ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
